MedTrace Logo

Optimal Reperfusion Strategy for STEMI Patients With Anticipated PPCI Delay

NCT04752345 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 632

Last updated 2021-02-12

No results posted yet for this study

Summary

The OPTIMAL-REPERFUSION trial will help determine whether reduced-dose facilitated PCI strategy improves clinical outcomes in patients with STEMI and anticipated PPCI delay

Conditions

  • ST Elevation Myocardial Infarction

Interventions

OTHER

Pharmacoinvasive strategy

Pharmacoinvasive treatment \[full-dose fibrinolysis combined with rescue PCI (in case of failed fibrinolysis) or routine early PCI (3 to 24 hours, in case of successful fibrinolysis)

OTHER

Reduced-dose facilitated PCI strategy

Reduced-dose facilitated PCI\[reduced-dose fibrinolysis,simultaneously transfer,immediate coronary angiography and andioplasty when arrived at PCI center(\<3 hours)\]

Sponsors & Collaborators

  • West China Hospital

    lead OTHER

Principal Investigators

  • Yong He · Department of Cardiology, West China Hospital of Sichuan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-31
Primary Completion
2022-09-30
Completion
2023-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04752345 on ClinicalTrials.gov